Evry, France, December 18, 2025 – AGS Therapeutics, a biotechnology company pioneering the development of Microalgae Extracellular Vesicles (MEVs) as a universal biological delivery platform, today announced the signing of an option agreement with a leading global cosmetics group.

Under the terms of the agreement, the cosmetics group has acquired a non-refundable, exclusive option to initiate, at its discretion, discussions with AGS Therapeutics regarding a potential exclusive license to use AGS’s MEV technology in the beauty and cosmetics field. This field represents a non-core area within AGS Therapeutics’ current strategic development, while remaining fully aligned with the broader applicability of its intellectual property portfolio.

In accordance with the parties’ commitments, neither the financial terms of the agreement nor the identity of the cosmetics group will be disclosed.

Importantly for AGS Therapeutics, the agreement does not involve any transfer of intellectual property and does not obligate AGS Therapeutics to enter into, or accept, any future licensing arrangement. The option is a stand-alone agreement that reflects the cosmetics industry's strong and growing interest in next-generation biological delivery technologies.

‍

A breakthrough biological delivery platform with significant potential for next-generation cosmetics

The MEVs developed by AGS Therapeutics are extracellular vesicles derived from microalgae, capable of efficiently carrying a wide range of molecules while preserving their stability and biological functionality.

Their intrinsic stability, favourable safety profile, unique biodistribution properties, and efficient cell-entry capabilities position MEVs as a promising innovation for advanced cosmetic and dermo-cosmetic applications, particularly those requiring precise biological interaction rather than superficial formulation effects.

‍

A scalable and sustainable biological manufacturing platform aligned with cosmetic industry values

In addition to their functional performance, MEVs offer significant advantages from a manufacturing and sustainability perspective. Derived from microalgae, MEVs are produced through a scalable, reproducible, and environmentally responsible bioprocess that relies on renewable biological resources and avoids the complexity and ethical constraints associated with mammalian cell-based systems.

This manufacturing profile aligns closely with the cosmetics industry’s increasing focus on sustainability, responsible sourcing, and green innovation, while maintaining the consistency, quality, and industrial robustness required for advanced cosmetic and dermo-cosmetic products.

‍

“This agreement represents an important strategic milestone for AGS Therapeutics. It highlights the versatility of our MEV platform, the strength and breadth of our intellectual property portfolio, and the growing interest in its applications beyond therapy. We are pleased to engage with a leading global cosmetics player and to continue expanding the value of our technology across multiple verticals.”

— Marie-Hélène Leopold, Chief Corporate Development Officer, AGS Therapeutics

‍

“The option granted provides a strong indication of the potential of our MEV technology in innovative applications outside AGS Therapeutics’ core focus. Our primary priority remains the advancement of our core clinical and preclinical programs, while selectively exploring high-value partnership opportunities that demonstrate the versatility of our platform.”

— Manuel Vega, Chief Executive Officer, AGS Therapeutics

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍

About AGS

AGS Therapeutics, based at Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative biologics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information visit www.ags-tx.com and www.ags-m.com.

‍

Forward looking statement

This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgement on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication. 

‍

Contacts 

Marie-Hélène Leopold | AGS Therapeutics | +33 (0)6 07 16 55 01 | mhl@ags-tx.com

Ana Vega | Markets & Listing | +33 (0)6 88 57 05 77 | av@markets-listing.com

‍

‍